{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:56:26Z","timestamp":1784944586996,"version":"3.55.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Several antifungals are available for the treatment of patients with invasive aspergillosis (IA). This study aims to evaluate the relative efficacy and safety of the first-line monotherapies in primary therapy of IA through network meta-analysis (NMA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, VIP database, Wanfang database, and China Biology Medicine for randomized controlled trials (RCTs) up to July 2023 that evaluated the efficacy and safety of monotherapies. We performed NMA with a frequentist random effects model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Primary outcomes were the all-cause mortality at week 12, and secondary outcomes included overall response rate, and incidence of adverse events (AEs) and severe adverse events (SAEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of three RCTs involving 1,368 participants (four antifungals) were included. The NMA showed that compared to amphotericin B deoxycholate (D-AmB), the triazoles (posaconazole (POS), isavuconazole (ISA) and voriconazole (VCZ)) can improve the overall response rate in primary therapy of IA, but only VCZ and ISA can reduce the all-cause mortality at week 12 for patients with proven and probable IA (VCZ vs D-AmB: RR = 0.66, 95%CI = 0.47\u20130.93, moderate certainty; ISA vs D-AmB: RR = 0.52, 95%CI = 0 .31\u20130.86, low certainty). ISA (SUCRA = 93.50%; mean rank, 1.20) seemed to be the most effective therapy in the above population. As to proven, probable, and possible IA patients, the triazoles were superior to D-AmB in terms of reducing all-cause mortality. Furthermore, the risk of AEs and SAEs was comparable for the three triazoles, but the risk of SAEs was significantly higher for D-AmB than others.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The efficacy and safety of triazoles are more favorable than D-AmB in the primary therapy of IA, with ISA being the optimal choice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO CRD42023407632.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1530999","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T07:45:08Z","timestamp":1736927108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey Sum-wing","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaye","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuimei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songsong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e233072","DOI":"10.1136\/bcr-2019-233072","article-title":"Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B","volume":"13","author":"Armstrong-James","year":"2020","journal-title":"BMJ Case Rep."},{"key":"B2","volume-title":"Posaconazole for the prophylaxis and treatment of invasive aspergillosis: a review of clinical effectiveness and guidelines","author":"Assasi","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/myc.13189","article-title":"The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain","volume":"64","author":"Azanza","year":"2021","journal-title":"Mycoses"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.3109\/13693786.2010.505204","article-title":"Clinical risk factors for invasive aspergillosis","volume":"49","author":"Baddley","year":"2011","journal-title":"Med. Mycol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/jof9020166","article-title":"Comparing the real-world use of isavuconazole to other anti-fungal therapy for invasive fungal infections in patients with and without underlying disparities: a multi-center retrospective study","volume":"9","author":"Batista","year":"2023","journal-title":"J. Fungi (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/14737167.2021.1981862","article-title":"Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada","volume":"22","author":"Beauchemin","year":"2022","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases\u2014estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J. Fungi"},{"key":"B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12879-015-0855-6","article-title":"Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"15","author":"Bow","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"B10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/MOH.0b013e328311890ce328311890c","article-title":"Invasive aspergillosis: diagnosis, prophylaxis and treatment","volume":"15","author":"Del Bono","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national Institute of Allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern. Med. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12879-019-3683-2","article-title":"Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden","volume":"19","author":"Floros","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Frederic","year":"2017","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eimc.2018.03.018","article-title":"Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC\/REIPI","volume":"37","author":"Garcia-Vidal","year":"2019","journal-title":"Enfermedades Infecc. Microbiol. clinica (English"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s1130-6343(05)73629-1","article-title":"(Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis)","volume":"29","author":"Grau Cerrato","year":"2005","journal-title":"Farm Hosp."},{"key":"B17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1292162","DOI":"10.3389\/fpubh.2023.1292162","article-title":"Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China","volume":"11","author":"Han","year":"2023","journal-title":"Front. Public Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-effectiveness analysis of isavuconazole vs. Voriconazole as first-line treatment for invasive aspergillosis","volume":"34","author":"Harrington","year":"2017","journal-title":"Adv. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1080\/03007995.2018.1502659","article-title":"Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis","volume":"34","author":"Herbrecht","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"B22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for systematic reviews of interventions version 5.0.1","author":"Higgins","year":"2008"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin. Transpl."},{"key":"B25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e074495","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"Bmj"},{"key":"B27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1524-4733.2006.00076.x","article-title":"Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany","volume":"9","author":"Jansen","year":"2006","journal-title":"Value Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1185\/030079905x65312","article-title":"Economic evaluation of voriconazole in the treatment of invasive aspergillosis in The Netherlands","volume":"21","author":"Jansen","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1358\/dot.2005.41.2.882661","article-title":"Second-generation azole antifungal agents","volume":"41","author":"Kale","year":"2005","journal-title":"Drugs Today (Barc)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jiac.2022.10.010","article-title":"Efficacy and safety of isavuconazole against deep-seated mycoses: a phase 3, randomized, open-label study in Japan","volume":"29","author":"Kohno","year":"2023","journal-title":"J. Infect. Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1128\/aac.00355-18","article-title":"Primary fungal prophylaxis in hematological malignancy: a network meta-analysis of randomized controlled trials","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/jcpt.12579","article-title":"A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients","volume":"42","author":"Leonart","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12879-024-09477-9","article-title":"Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/s0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e13832","DOI":"10.1111\/tid.13832","article-title":"Antifungal prophylaxis in adult lung transplant recipients: uncertainty despite 30 years of experience. A systematic review of the literature and network meta-analysis","volume":"24","author":"Marinelli","year":"2022","journal-title":"Transpl. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.idnow.2021.04.002","article-title":"Clinical manifestations, diagnosis, and treatment outcome of CNS aspergillosis: a systematic review of 235 cases","volume":"51","author":"Meena","year":"2021","journal-title":"Infect. Dis. Now."},{"key":"B39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/jof5030079","article-title":"Central nervous system infections due to Aspergillus and other hyaline molds","volume":"5","author":"Miceli","year":"2019","journal-title":"J. Fungi (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1128\/aac.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"610","DOI":"10.12688\/f1000research.14770.3","article-title":"Estimating the contribution of studies in network meta-analysis: paths, flows and streams","volume":"7","author":"Papakonstantinou","year":"2018","journal-title":"F1000Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/bmt.2009.17","article-title":"Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis","volume":"44","author":"Reinwald","year":"2009","journal-title":"Bone Marrow Transpl."},{"key":"B45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1155\/2004\/183087","article-title":"An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada","volume":"15","author":"Rotstein","year":"2004","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1128\/aac.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system","volume":"58","author":"Schwartz","year":"2019","journal-title":"Med. Mycol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1439-0507.2007.01345.x","article-title":"Poor efficacy of amphotericin B-based therapy in CNS aspergillosis","volume":"50","author":"Schwartz","year":"2007","journal-title":"Mycoses"},{"key":"B49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/myc.13410","article-title":"Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: a systematic review and meta-analysis","volume":"65","author":"Shi","year":"2022","journal-title":"Mycoses"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s40265-016-0652-6","article-title":"Isavuconazole: a review in invasive aspergillosis and mucormycosis","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2147\/idr.S203579","article-title":"Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis","volume":"12","author":"Su","year":"2019","journal-title":"Infect. Drug Resist"},{"key":"B52","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: a comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"B53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/aac.01216-08","article-title":"Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e2017652","DOI":"10.1001\/jamanetworkopen.2020.17652","article-title":"Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: a systematic review and network meta-analysis","volume":"3","author":"Wang","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B56","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/jac\/dkh535","article-title":"Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients","volume":"55","author":"Wenzel","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1399-3062.2007.00210.x","article-title":"Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis","volume":"9","author":"Wingard","year":"2007","journal-title":"Transpl. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1530999\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T07:45:14Z","timestamp":1736927114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1530999\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":57,"alternative-id":["10.3389\/fphar.2024.1530999"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1530999","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"article-number":"1530999"}}